Indian Study Shows No Survival Benefit of Plasma in COVID-19
Indian Study Shows No Survival Benefit of Plasma in COVID-19
A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.
Indian Study Shows No Survival Benefit of Plasma in COVID-19
Indian Study Shows No Survival Benefit of Plasma in COVID-19

A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.

A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.

randomized human studies
Steroid Drugs Are an Effective Treatment for Severe COVID-19: WHO
Steroid Drugs Are an Effective Treatment for Severe COVID-19: WHO
Catherine Offord | Sep 3, 2020
A meta-analysis of seven randomized controlled trials concludes that dexamethasone and other corticosteroids reduce 28-day mortality in seriously ill patients.
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Shawna Williams | Aug 14, 2020
Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.
A New Way to Establish Cause and Effect in Epidemiology?
A New Way to Establish Cause and Effect in Epidemiology?
Rachael Moeller Gorman | Jan 1, 2020
A technique called Mendelian randomization is overturning the conclusions of observational studies in public health. But researchers question whether the method can overcome its fundamental limitations.
Parkinson’s Researcher Notches 17 Retracted Papers
Parkinson’s Researcher Notches 17 Retracted Papers
Aggie Mika | Sep 13, 2017
Scientific misconduct motivated Yoshihiro Sato’s three additional retractions last month; his institution doesn’t respond.